Mechanisms of methotrexate resistance in osteosarcoma

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 621-627

  Guo, Wei ^a   Healey, John H ^a   Meyers, Paul A ^a   Ladanyi, Marc ^a   Huvos, Andrew G ^a   Bertino, Joseph R ^a   Gorlick, Richard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; TRIMETREXATE;

ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; EXCISION; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0033001234     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Meyers, P. A., Heller, G., Healey, J. H., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V., and Rosen, G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol., 10: 5-15, 1992.
2. Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A., and Healey, J. Intensification of preoperative chemotherapy for osteogenic sarcoma: the results of the Memorial Sloan-Kettering (T12) protocol. J. Clin. Oncol., 16: 2452-2458, 1998.
3. Jaffe, N., Frei, E., Watts, H., and Traggis, D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat. Rep., 62: 259-264, 1978.
4. Saeter, G., Alvegard, T. A., Elomaa, I., Stenwig, A. E., Holmstrom, T., and Solheim, O. P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J. Clin. Oncol., 9: 1766-1775, 1991.
5. Bertino, J. R. Karnofsky memorial lecture. Ode to methotrexate. J. Clin. Oncol., 11: 5-14, 1993.
6. Lin, J. T., Tong, W. P., Trippett, T. M., Niedzwiecki, D., Tao, Y., Tan, C., Steinherz, P., Schweitzer, B. I., and Bertino, J. R. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leukemia Res, 15: 1191-1196, 1991.
7. Gorlick, R., Goker, E., Trippett, T., Wealtham, M., Banerjee, D., and Bertino, J. R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med., 335: 1041-1048, 1996.
8. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., Flintoff, W. F., and Bertino, J. R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89: 1013-1018, 1996.
9. Goker, E., Waltham, M., Kheradpour, A., Trippett, T., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P., Tan, C., Berman, E., and Bertino, J. R. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood, 86: 677-684, 1995.
10. Matherly, L. H., Taub, J. E., Wong, S. C., Simpson, P. M., Ekizian, R., Buck, S., Williamson, M., Amylon, M., Pullen, J., Camitta, B., and Ravindranath, Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood, 90: 578-589, 1997.
11. Ferrari, S., Sassoli, V., Orlandi, M., Strazzari, S., Puggiolo, C., Battistini, A., and Bacci, G. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J. Chemother, 5: 135-141, 1993.
12. Bacci, G., Ferrari, S., Delepine, N., Bertoni, F., Picci, P., Mercuri, M., Bacchini, P., Brach del Prever, A., Tienghi, A., Comandone, A., and Campanacci, M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol., 16: 658-663, 1998.
13. Delepine, N., Delepine, G., Bacci, G., Rosen, G., and Desbois, J. C. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic sarcoma. Cancer (Phila.), 78: 2127-2135, 1996.
14. Leung, S., Marshall, G. M., Al Mahr, M., Tobias, V., Lee, D. B., and Hughes, D. O. Prognostic significance of chemotherapy dosage characteristic in children with osteogenic sarcoma. Med. Pediatr. Oncol., 28: 179-182, 1997.
15. Meyer, W. H., Loftin, S. K., Houghton, J. A., and Houghton, P. J. Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosarcoma xenografts. Cancer Commun., 2: 219-229, 1990.
16. Meyer, P. A., and Gorlick, R. Osteosarcoma. Pediatr. Clin. North Am., 44: 973-990, 1997.
17. Huvos, A. G., Rosen, G., and Marcove, R. C. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch. Pathol. Lab. Med., 101: 14-18, 1977.
18. Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., and Urban, C. Preoperative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer (Phila.), 49: 1221-1230, 1982.
19. Ausubel, F. M., Brent, R., and Kingston, R. E. Preparation of genomic DNA from mammalian tissue. In: F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhi (eds.), Current Protocols in Molecular Biology, Vol. 2, pp. 2.1-2.2.2. New York: John Wiley & Sons, Inc., 1996.
20. Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Volkenandt, M., Shea, L. C., Aigner, K., Gustavsson, B., Leichman, L., Frosing, R., Ray, M., and Danenberg, P. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res, 52: 108-113, 1992.
21. Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98: 503-508, 1975.
22. Meyers, P. A., Heller, G., Healey, J. H., Huvos, A., Applewhite, A., Sun, M., and LaQuaglia, M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J. Clin. Oncol., 11: 449-453, 1993.
23. Scotlandi, K., Serra, M., Nicoletti, G., Vaccari, M., Manara, M. C., Nini, G., Landuzzi, L., Colacci, A., Bacci, G., Bertoni, F., Picci, P., Campanacci, M., and Baldini, N. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res., 56: 2434-2440, 1996.
24. Baldini, N., Scotlandi, K., Barbanti-Brodano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., and Campanacci, M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med., 333: 1380-1385, 1995.
25. Cole, P. D., Gorlick, R., Longo, G., Deckert, P. M., Banerjee, D., and Bertino, J. R. Development of a quantitative RT-PCR assay for the measurement of γ-glutamyl hydrolase (GGH). Proc. Am. Assoc. Cancer Res., 39: 433, 1998.
26. Gorlick, R., Metzger, R., Danenberg, K. D., Salonga, D., Miles, J. S., Longo, G. S. A., Fu, J., Banerjee, D., Klimstra, D., Jhanwar, S., Danenberg, P. V., Kemeny, N., and Bertino, J. R. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol., 16: 1465-1469, 1998.
27. Banerjee, D., Gorlick, R., Fu, J., Danenberg, K., Salonga, D., Park, J. M., Danenberg, P., Kemeny, N., and Bertino, J. R. Elevated thymidylate synthase (TS) expression in the metastases of colon cancer correlates with increases in E2F expression. Proc. Am. Assoc. Cancer Res., 39: 433, 1998.
28. Wells, J. M., Illenye, S., Magae, J., Wu, C. L., and Heintz, N. H. Accumulation of E2F-4. DP-1 DNA binding complexes with induction of dhfr gene expression during the G1 to S phase transition. J. Biol. Chem., 272: 4483-4492, 1997.
29. Li, W. W., Fan, J. G., Hochhauser, D., Banerjee, D., Zielinski, Z., Almasan, A., Yin, Y., Kelly, R., Wahl, G. M., and Bertino, J. R. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl. Acad. Sci. USA, 92: 10436-10440, 1995.
30. Fan, J. G., and Bertino, J. R. Functional roles of E2F in cell cycle regulation. Oncogene, 14: 1191-1200, 1997.
31. Li, W. W., Fan, J. G., Hochhauser, D., and Bertino, J. R. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res. 57: 2193-2199, 1997.
32. Pellin, A., Ferrero-Boix, J., Carpio, D., Lopez-Terrada, D., Carda, C., Navarro, S., Peydro-Olaya, A., Triche, T. J., and Llombart-Bosch, A. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn. Mol. Pathol., 6: 333-341, 1997.
33. Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., Brunat-Mentigny, M., Patricot, L. M., and Oberling, F. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J. Clin. Oncol., 14: 467-472, 1996.
34. Miller, C. W., Aslo, A., Campbell, M. J., Kawamata, N., Lampkin, B. C., and Koeffler, H. P. Alterations of the p53. Rb and MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol., 122: 559-565, 1996.
35. Wadayama, B., Toguchida, J., Shimizu, T., Ishizaki, K., Sasaki, M. S., Kotoura, Y., and Yamamuro, T. Mutation spectrum of the retinoblastoma gene in osteosarcoma. Cancer Res., 54: 3042-3048, 1994.
36. Diddens, H., Niethammer, D., and Jackson, R. C. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res., 43: 5286-5292, 1983.
37. Li, W. W., and Bertino, J. R. Inability of leucovorin to rescue a naturally methotrexate resistance human soft tissue sarcoma cell line from trimetrexate cytotoxicity. Cancer Res., 52: 6866-6870, 1992.
38. Lacerda, J. F., Goker, E., Kheradpour, A., Dennig, D., Elisseyeff, Y., Jagiello, C., O'Reilly, R. J., and Bertino, J. R. Selective treatment of SCID mice bearing methotrexate transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood, 85: 2675-2679, 1995.
39. Tkaczewski, L., Tong, W. P., Spriggs, D., Bertino, J. R., Capizzi, R. L., and Kamen, B. A. Trimetrexate (TMTX) oral bioavailability and lack of cross resistance with HD-MTX in patients with recurrent osteosarcoma. Proc. Am. Soc. Clin. Oncol., 15: 1504, 1996.